India, May 28 -- ORIC Pharmaceuticals Inc. (ORIC) announced potentially best-in-class preliminary efficacy and safety data from the ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).
ORIC closed Wednesday's regular trading at $5.97 up $0.19 or 3.29%. The stock further gained $1.11 or 18.59%.
The company noted that Broad and deep PSA responses were achieved in patients with mCRPC, with a 59% PSA50 response rate (47% confirmed, with one additional response pending confirmation) and a 24% PSA90 response rate, all confirmed.
PSA responses were observed across all ORIC-944 dose levels and at comparable rates when combined...